Detalhe da pesquisa
1.
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol
; 201(6): 1116-1124, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004981
2.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35615931
3.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer
; 124(14): 2956-2963, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
4.
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
Cancer
; 119(24): 4284-9, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24105694
5.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
N Engl J Med
; 363(26): 2511-21, 2010 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21175313
6.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia
; 35(8): 2332-2345, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483613
7.
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Blood Adv
; 3(20): 3033-3037, 2019 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648325
8.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res
; 25(22): 6606-6613, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292142
9.
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
J Clin Oncol
; 35(3): 298-305, 2017 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28095277
10.
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
J Clin Oncol
; 23(30): 7676-84, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16186596
11.
Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Hum Pathol
; 37(11): 1458-64, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16949922
12.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Semin Hematol
; 40(2 Suppl 2): 92-7, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12783382
13.
Chronic myeloid leukemia associated with B-cell chronic lymphocytic leukemia: evidence of two separate clones as shown by combined cell-sorting and fluorescence in situ hybridisation.
Leuk Lymphoma
; 44(5): 867-9, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12802927
14.
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Leuk Res
; 35(1): 80-6, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20605207
15.
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
J Clin Oncol
; 27(16): 2668-76, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19414681
16.
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. / Recommandations pour la gestion des effets indésirables du traitement par dasatinib (Sprycel) au cours de la leucémie myéloïde chronique et des leucémies aiguës lymphoblastiques à chromosome Philadelphie.
Bull Cancer
; 95(9): 805-11, 2008 Sep.
Artigo
em Francês
| MEDLINE | ID: mdl-18829412
17.
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
J Clin Oncol
; 24(36): 5703-10, 2006 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17116939
18.
[Cardiac effects of cytokines produced after rituximab infusion]. / Effets cardiaques des cytokines relarguées lors de l'administration de rituximab.
Bull Cancer
; 92(9): 769-71, 2005 Sep.
Artigo
em Francês
| MEDLINE | ID: mdl-16203266
19.
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Br J Haematol
; 129(3): 403-10, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15842665
20.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Blood
; 102(13): 4298-305, 2003 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12933584